

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:

Application No. 10/590,797

Confirmation No. 2176

Hans-Peter BUCHSTALLER et al.

.

Examiner: Unassigned

Filed: August 25, 2006

Art Unit: Unassigned

For: ISOQUINOLINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of the listed document is being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Attorney Docket No. 24945-0040.US

RELEVANCE

These documents came to the Applicants' attention during a search of the

corresponding international application. A copy of the International Search Report setting

forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37

CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required

in connection with its filing. However, the Commissioner is hereby authorized to charge any

deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the

Examiner and be made of record in the present application and that an initialed copy of Form

PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date.____t

HELLER EHRMAN LLP

1717 Rhode Island Avenue, NW

Washington, D.C. 20036

Telephone:

(202) 912-2000

Facsimile:

(202) 912-2020

Patricia D. Granados

Attorney for Applicant Reg. No.: 33,683

.

Customer No. 26633

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PTC)		Complete if Known		
				Application Number	10/590,797	
INFC	RMATION	DIS	CLOSURE	Filing Date	August 25, 2006	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Hans-Peter BUCHSTALLER et al.	
				Group Art Unit	Unassigned	
	(use as many she	ets as	necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	24945-0040.US	

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.	U.S. P	atent Document	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Number (if known)		Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	 						
	<u> </u>						
	-						

				FOREIGN	PATENT DOCUMENTS			
Examiner Initials*	Cite No. ¹				Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
	A01	wo	03/097586	Α	Janssen Pharm. et al.	11/27/2003		
	A02	EP	1 256 574	A1	Kirin Beer Kabushiki Kaisha	11/13/2002		
	A03	wo	93/18028	A1	Smithkline Beecham PLC	9/16/1993		
	A04	wo	02/085857	A2	Bayer Corp. et al.	10/31/2002		
	A05	wo	02/085859	A1	Bayer Corp. et al.	10/31/2002		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Please type a plus sign (+) inside this box PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons at the paperwork Reduction of Information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
WITCH ATION DIGGLOCKED	Application Number	10/590,797 August 25, 2006			
INFORMATION DISCLOSURI	rilling Date				
STATEMENT BY APPLICANT	First Named Inventor	Hans-Peter BUCHSTALLER et al.			
	Group Art Unit	Unassigned			
(use as many sheets as necessary)	Examiner Name	Unassigned			
Sheet 2 of 2	Attorney Docket Number	24945-0040.US			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	T
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A06	PING CHEN ET AL, "Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors", Bioorganic & Medicinal Chemistry Letters, 2003, pp. 1345-1348, vol. 13, no. 7, 2003, XP002329515 GBOXFORD page 1345; figure 2; table 2	
•			

Examiner	Date Considered		
Signature		<u> </u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.